Eli Lilly’s Baqsimi (glucagon 3mg) Nasal Powder Receives FDA’s Approval for the Treatment of Severe Hypoglycemia

 Eli Lilly’s Baqsimi (glucagon 3mg) Nasal Powder Receives FDA’s Approval for the Treatment of Severe Hypoglycemia

Eli Lilly Initiates P-III Study Evaluating Baricitinib in Hospitalized Patients with COVID-19

Shots:

  • The FDA’s approval follows multiple studies with various age group evaluating baqsimi (glucagon, 3mg) nasal powder vs glucagon injection formulation in patients with diabetes aged 4yrs and older
  • Collective study results demonstrated noninferiority data to glucagon injection formulation in raising blood glucose level after insulin-induced hypoglycemia, 100% patients reach treatment success  i.e, increase in plasma glucose levels to ≥ 70 mg/dL or a ≥20 mg/dL rise in plasma glucose from nadir within 30 minutes post receiving glucagon
  • Baqsimi is a dry nasal spray form of glucagon, ready to use with no reconstitution or priming required in a single, fixed 3 mg dose, to be absorbed in the nose and is expected to be available within one month in the US

Click here to­ read full press release/ article | Ref: Eli Lilly | Image: Amife

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post